Shares of Exelixis, Inc. (NASDAQ:EXEL) have received a consensus rating of “Buy” from the thirteen research firms that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $19.51.
Several research firms have recently weighed in on EXEL. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research note on Friday. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Exelixis in a research note on Monday, June 5th. Needham & Company LLC began coverage on shares of Exelixis in a research note on Friday, March 31st. They set a “buy” rating and a $28.00 price target for the company. Cann reaffirmed a “hold” rating on shares of Exelixis in a research note on Wednesday, April 19th. Finally, Zacks Investment Research downgraded shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 3rd.
In other Exelixis news, insider Patrick J. Haley sold 5,000 shares of Exelixis stock in a transaction on Tuesday, May 30th. The shares were sold at an average price of $18.46, for a total value of $92,300.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Stelios Papadopoulos sold 10,000 shares of Exelixis stock in a transaction on Monday, March 20th. The stock was sold at an average price of $21.66, for a total transaction of $216,600.00. Following the completion of the transaction, the director now directly owns 1,238,471 shares in the company, valued at $26,825,281.86. The disclosure for this sale can be found here. Insiders sold 765,468 shares of company stock worth $16,847,040 over the last ninety days. Corporate insiders own 5.10% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in EXEL. FMR LLC raised its position in Exelixis by 24.2% in the fourth quarter. FMR LLC now owns 42,910,087 shares of the biotechnology company’s stock valued at $639,789,000 after buying an additional 8,361,226 shares in the last quarter. Vanguard Group Inc. raised its position in Exelixis by 12.8% in the first quarter. Vanguard Group Inc. now owns 23,735,071 shares of the biotechnology company’s stock valued at $514,339,000 after buying an additional 2,696,877 shares in the last quarter. BlackRock Inc. raised its position in Exelixis by 33,678.5% in the first quarter. BlackRock Inc. now owns 19,155,466 shares of the biotechnology company’s stock valued at $415,099,000 after buying an additional 19,098,757 shares in the last quarter. State Street Corp raised its position in Exelixis by 2.1% in the first quarter. State Street Corp now owns 7,710,338 shares of the biotechnology company’s stock valued at $167,087,000 after buying an additional 157,199 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. raised its position in Exelixis by 237.5% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 5,041,260 shares of the biotechnology company’s stock valued at $109,244,000 after buying an additional 3,547,665 shares in the last quarter. 80.69% of the stock is currently owned by institutional investors and hedge funds.
Exelixis (NASDAQ:EXEL) traded up 0.10% on Monday, reaching $19.26. The company’s stock had a trading volume of 3,678,824 shares. The firm has a 50-day moving average of $20.44 and a 200-day moving average of $19.81. Exelixis has a one year low of $7.20 and a one year high of $24.85. The company has a market capitalization of $5.63 billion, a PE ratio of 917.14 and a beta of 1.98.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Monday, May 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.06. The business had revenue of $80.90 million during the quarter, compared to the consensus estimate of $65.23 million. Exelixis had a net margin of 1.37% and a return on equity of 126.82%. The firm’s quarterly revenue was up 425.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.27) earnings per share. Analysts predict that Exelixis will post $0.18 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Exelixis, Inc. (EXEL) Receives Consensus Recommendation of “Buy” from Brokerages” was posted by WKRB News and is owned by of WKRB News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.wkrb13.com/markets/2231045/exelixis-inc-exel-receives-consensus-recommendation-of-buy-from-brokerages.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2231045/exelixis-inc-exel-receives-consensus-recommendation-of-buy-from-brokerages.html
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.